- Rank in Search Criteria: 5621
World Rank (Jan-05-2024): 19,166
World Rank (Jul-30-2023): 19166
Market Cap (Jul-30-2023): 0.16 Billion USD
World Rank (Jan-2022): 14,609
Market Cap (Jan-2022): 0.42 Billion USDHeadquarters Country: USA
- Rank in Search Criteria: 5622
World Rank (Jan-05-2024): 19,166
World Rank (Jul-30-2023): 19166
Market Cap (Jul-30-2023): 0.16 Billion USD
Headquarters Country: USA
- Rank in Search Criteria: 5623
World Rank (Jan-05-2024): 19,167
World Rank (Jul-30-2023): 19167
Market Cap (Jul-30-2023): 0.16 Billion USD
World Rank (Jan-2022): 16,966
Market Cap (Jan-2022): 0.29 Billion USD
- Rank in Search Criteria: 5624
World Rank (Jan-05-2024): 19,177
World Rank (Jul-30-2023): 19177
World Rank (Jan-2022): 19,177
Market Cap (Jan-2022): 0.19 Billion USDHeadquarters Country: USA Company Profile: Humanigen, Inc is a Clinical Stage Biopharmaceutical company developing immunology and immuno oncology portfolio of monoclonal antibodies. It is having 68.3 million USD as on 2020. The headquarters is in USA.
- Rank in Search Criteria: 5625
World Rank (Jan-05-2024): 19,178
World Rank (Jul-30-2023): 19178
Market Cap (Jul-30-2023): 0.16 Billion USD
World Rank (Jan-2022): 18,307
Market Cap (Jan-2022): 0.23 Billion USD
- Rank in Search Criteria: 5626
World Rank (Jan-05-2024): 19,178
World Rank (Jul-30-2023): 19178
World Rank (Jan-2022): 19,178
Market Cap (Jan-2022): 0.19 Billion USDHeadquarters Country: USA Annual Revenue in USD: 0 Million USD
Annual Net Income in USD: -33 Million USD
Annual Results for Period ending: Dec-2020 ending yearEmployee Count: 52
Employee Count as of Date: As on September-2020
Company Profile: Silverback Therapeutics is a Clinical Stage Biopharmaceutical company leveraging proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. It is having 51 employees as on 2020. The headquarters is in USA.
- Rank in Search Criteria: 5627
World Rank (Jan-05-2024): 19,178
Market Cap (Jan-05-2024): 0.16 Billion USD
World Rank (Jul-30-2023): 20700
Market Cap (Jul-30-2023): 0.12 Billion USD
World Rank (Jan-2022): 21,715
Market Cap (Jan-2022): 0.12 Billion USDHeadquarters Country: USA Annual Revenue in USD: 710 Million USD
Annual Net Income in USD: 20 Million USD
Annual Results for Period ending: Dec-2020 ending year
- Rank in Search Criteria: 5628
World Rank (Jan-05-2024): 19,179
Market Cap (Jan-05-2024): 0.16 Billion USD
World Rank (Jul-30-2023): 19546
Market Cap (Jul-30-2023): 0.15 Billion USD
World Rank (Jan-2022): 11,987
Market Cap (Jan-2022): 0.64 Billion USD
- Rank in Search Criteria: 5629
World Rank (Jan-05-2024): 19,188
Market Cap (Jan-05-2024): 0.16 Billion USD
World Rank (Jul-30-2023): 19973
Market Cap (Jul-30-2023): 0.14 Billion USD
World Rank (Jan-2022): 9,582
Market Cap (Jan-2022): 0.97 Billion USDHeadquarters Country: USA Annual Revenue in USD: 1 Million USD
Annual Net Income in USD: -303 Million USD
Annual Results for Period ending: Dec-2021 ending yearEmployee Count: 317
Employee Count as of Date: As on 2021
Company Profile: Inovio Pharmaceuticals is a Biotechnology company focused on the discovery and developing precisely designed DNA medicines to potentially treat and protect people from a range of serious and life threatening diseases and infections. The company annual revenue is 4 million USD and 281 employees as on 2019. The headquarters is in USA.
- Rank in Search Criteria: 5630
World Rank (Jan-05-2024): 19,190
World Rank (Jul-30-2023): 19190
Headquarters Country: USA